Biomarker for the Classification of Melanocytic Neoplasms

This invention relates to potential transcriptomic biomarkers using gene- or protein-level expression of individual or a combination of the 23 genes/proteins to accurately differentiate between low-risk, benign from high-risk, malignant melanocytic neoplasms. This approach aims to improve the accuracy of melanoma diagnosis and reduce diagnostic uncertainty.

Background: 
A melanocytic neoplasm refers to a growth or tumor that originates from melanocytes and can be classified as benign (like melanocytic nevi or moles) or malignant (like melanoma, the deadliest form of skin cancer). Many melanocytic lesions appear histologically ambiguous, therefore biomarkers such as ones developed in this invention, can provide objective data to support pathologists and avoid equivocal diagnoses that directly impact survival, treatment strategy, and patient quality of life.

Applications: 

• Melanocytic neoplasm biomarker
• Melanoma diagnostic
• Predictive oncology
• Personalized cancer treatment

Advantages: 

• Accurately differentiates between benign nevi and malignant melanocytic neoplas
• Improved accuracy of melanoma diagnosis
• Based on a 23-gene transcriptomic signature